Month: January 2024

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces positive results for the phase 2 trial of Miconazole Domiphen-Bromide (MCZ-DB) in patients with acute vulvovaginal candidiasis. The phase 2 trial of MCZ-DB was a 12-week,...

In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start to meet our financial guidance for this fiscal year. Whereas the first year of our transformative ZOOM IN strategy revolved around re-building our financial foundation, this second year is dedicated to accelerated growth at higher margins. I am excited to continue our trajectory along with my...

Regulated Information – Inside Information 30 January 2024, 7:00 a.m. CET, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’) announces the acquisition of 21 hectares, currently used as a car park, located on part of the Stellantis site in Mulhouse, France. Two years after its arrival on the French market, VGP now has a secure 73-hectare portfolio of land on which to develop almost 350,000 m² of industrial, logistics and business premises. At the end of 2024, VGP will complete the first delivery of 40,000 m² on the Petit-Couronne site in Rouen. In a dynamic region that is currently experiencing a shortage of industrial and logistics space, this new park will help to meet the growing needs of businesses. Located in the commune of Sausheim, near Mulhouse, the site benefits from an exceptional location and accessibility, at the junction...

               Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announced that Prof. Piotr Trzonkowski, CEO, has co-authored a peer-reviewed article in Frontiers in Immunology, the world’s fifth most-cited immunology journal, laying out the decades of scientific progress underlying the company’s portfolio of ground-breaking clinical-stage therapies for diseases such as Type-1 Diabetes (T1D) and Multiple Sclerosis (MS). Prof. Trzonkowski, together with other researchers from the Medical University of Gdańsk, joined contributing authors from the teams of Prof. Ye Htun Oo at University of Birmingham, Prof. Anke Fuchs from the Technical University of Dresden, and Prof. Natalia Marek-Trzonkowska from the International...

With the founding of “Feintool System Parts India Pvt Ltd” and a new production site in the metropolitan region of Pune, Feintool is consolidating its strategic position as an important supplier of high-precision parts in Asian automotive production. With an initial investment of CHF 15 million, Feintool is moving closer to long-standing customers who already produce in the region. “Feintool System Parts India Pvt Ltd” is establishing its presence in a promising market and reducing its CO2 footprint through significantly lower delivery-related emissions. Feintool production in Pune is expected to start in summer 2025. «With our expansion into India, we are meeting the needs of our long-standing customers, entering a promising geographic market and contributing to shorter and, therefore, ecologically sustainable...

AURI Token Listing on Global Exchange DALLAS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Auri Inc. (OTCPK: “AURI”) (the “Company”) Today, AURI the company is proud to announce a partnership and listing on Salavi Exchange. AURI Inc. has been informed that the listing will take place at 10 am UDT on January 30, 2024. This listing will allow the AURI Token to be traded on a CEX with USDT pairing. This will allow for an increased market exposure and help grow the AURI Token Project, Both Salavi and AURI have agreed to post information pertaining to the partnership and conduct airdrops throughout this partnership, AURI Inc. is excited for where this partnership will lead. Our experience has been stellar with Salavi. Their customer Service, knowledge and expertise has been incredible. We look forward to the next steps of...

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in mainland China, Macau SAR and the United States — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth...

New program streamlines tiering structure, with transparent pricing, cumulative discounts, and elevated deal registration incentives for valued partners BANGKOK, Thailand, Jan. 29, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading AI-powered, cloud-delivered cyber security platform provider, today announced the launch of its innovative new Partner Program. Amidst an ever-evolving cyber security landscape, this program aims to strengthen partner capabilities and fuel growth. The cyber security sector is experiencing rapid growth and transformation. According to Canalys, cyber security spending hit $19 billion recently, reflecting the increasing need for collaborative security solutions. As technology evolves, so too do cyber threats, prompting an increased need for a unified cyber security...